<DOC>
	<DOCNO>NCT01231659</DOCNO>
	<brief_summary>This multi-center , Israeli phase II open label study evaluate treatment RAD001 ( 10 mg daily ) combine letrozole ( 2.5 mg daily ) postmenopausal woman recurrence progression Tamoxifen , Anastrozole Examestane . There treatment specifically approve recurrence progression AIs . Available option , base common clinical practice several treatment guideline ( e.g . NCCN treatment guideline 2008 ) , include fulvestrant . Combining RAD001 letrazole rational approach treatment advance Brest Cancer , offer potential inhibition tumor cell growth\ proliferation anti angiogenesis time potentially prevent development letrazole resistance .</brief_summary>
	<brief_title>Safety Efficacy RAD001 ( Everolimus ) Combination With Letrozole Treatment Postmenopausal Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman estrogen receptor positive locally advanced metastatic breast cancer document recurrence progression Tamoxifen , Anastrozole Examestane . Refractory disease hormonal therapy define : 1 . Recurrence , within 12 month end , adjuvant treatment Tamoxifen , Anastrozole , Exemestane . 2 . Recurrence , within 24 month end , adjuvant treatment Letrozole . 3 . Progression Tamoxifen , Anastrozole Exemestane treatment locally advance metastatic breast cancer . Prior use chemotherapy letrozole Advanced Breast Cancer mTOR inhibitor last anticancer treatment prior study entry . Patients must radiological evidence recurrence progression last therapy prior study entry . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>RAD001 ( Everolimus )</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic Breast cancer</keyword>
	<keyword>Estrogen receptor positive</keyword>
	<keyword>Failure Tamoxifen</keyword>
	<keyword>Anastrozole Examestane</keyword>
</DOC>